FDA approves labeling supplement for Jazz's Zepzelca (lurbinectedin)
The FDA signed off on a labeling change for Zepzelca, Jazz Pharmaceuticals' lurbinectedin, with a standard review priority.
Jazz Pharmaceuticals had one regulatory action this week involving its approved oncology product.
- The FDA approved a labeling supplement (submission number 13) for Zepzelca, an intravenous powder formulation containing lurbinectedin at 4mg per vial, sponsored by Jazz, under standard review priority.1 The approval letter is dated October 1, 2026, with a submission status date of September 30, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.